Cipla (LUX:CIPLA) ROE % Adjusted to Book Value: 1.63% (As of Mar. 2026)


LUX:CIPLA Cipla Ltd LUX:CIPLA
94 GF Score
Price $18.10
GF Value $19.69
! 5 Warning Signs
View Full Analysis

What is Cipla ROE % Adjusted to Book Value?

Cipla LUX:CIPLA 94 ROE % Adjusted to Book Value is 1.63% as of Mar. 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 94/100 and a GF Value™ of $19.69. The stock has 5 warning signs investors should review.

Cipla's ROE % for the quarter that ended in Mar. 2026 was 6.44%. Cipla's PB Ratio for the quarter that ended in Mar. 2026 was 3.94. Cipla's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 1.63%.

Cipla ROE % Adjusted to Book Value Related Terms

Cipla ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Cipla's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla ROE % Adjusted to Book Value Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 3.91 3.65 4.41 2.90

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 0.00 4.19 0.00 1.63

LUX:CIPLA vs ZTS, UTHR: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cipla ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Cipla's ROE % Adjusted to Book Value falls into.


LUX:CIPLA
94GF Score
Cipla Ltd LUX:CIPLA
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla ROE % Adjusted to Book Value Calculation

Cipla's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=11.43% / 3.94
=2.90%

Cipla's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=6.44% / 3.94
=1.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 1.63% mean?
Cipla (LUX:CIPLA) has a ROE % Adjusted to Book Value of 1.63% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cipla and its competitors.
Is Cipla's ROE % Adjusted to Book Value too high?
Cipla's current ROE % Adjusted to Book Value is 1.63%. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's ROE % Adjusted to Book Value compare to ZTS and UTHR?
Cipla's ROE % Adjusted to Book Value of 1.63% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Cipla and its competitors. Cipla's current ROE % Adjusted to Book Value is 1.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current ROE % Adjusted to Book Value of 1.63%. The stock's GF Value™ is $19.69, compared to a current price of $18.10 — trading 8.1% below its estimated fair value. The current ROE % Adjusted to Book Value is 1.63%. Cipla's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current ROE % Adjusted to Book Value is 1.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.1% below its estimated GF Value™ of $19.69.

Key valuation signals for LUX:CIPLA:

  • ROE % Adjusted to Book Value: 1.63%
  • GF Value™: $19.69 vs. price of $18.10 (8.1% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
94GF Score

Get the complete analysis for LUX:CIPLA

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.69
GF Value